An evaluation of the efficacy of vasoactive intestinal polypeptide antagonists in vivo in the anaesthetized dog

Pharmacology

Volumn 66, Issue 4, 2002, Pages 206-210

  Markos, F ^a   Hennessy, B A ^b   Fitzpatrick, M ^b   O'Sullivan, J ^b   Snow, H M ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b NONE

Author keywords

D p Cl Phe6, Leu17 VIP; Heart, dog; PACAP (6 27); VIP (6 28); VIP antagonists

Indexed keywords

ATENOLOL; ATROPINE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE[DEXTRO 4 CHLORO 6 PHENYLALANINE 17 LEUCINE];

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HEART RATE; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; DOGS; HEART RATE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE;

EID: 0036970155     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065535     Document Type: Article

References (23)

1. Costa M, Furness JB, Gibbins IL, Morris JL, Bornstein JC, Llewellyn-Smith IJ, Murphy R: Colocalization of VIP with other neuropeptides and neurotransmitters in the autonomic nervous system. Ann NY Acad Sci 1988;527:103-109.
2. Lundberg J: Evidence for coexistence of vasoactive intestinal polypeptide (VIP) and acetylcholine in neurons of cat exocrine glands: Morphological, biochemical and functional studies. Acta Physiol Scand Suppl 1981;496:1-57.
3. Weihe E, Reinecke M, Forssmenn WG: Distribution of vasoactive intestinal polypeptide-like immunoreactivity in the mammalian heart. Cell Tissue Res 1984;236:527-540.
4. Wharton J, Gubenkian S: Peptides in the mammalian cardiovascular system. Experientia 1987;43:821-832.
5. Rigel DF: Effects of neuropeptides on heart rate in dogs: Comparison of VIP, PHI, NPY, CGRP, and NT. Am J Physiol 1988;255:H311-H317.
6. Markos F, Snow HM: The potentiation of sinus arrhythmia by vasoactive intestinal polypeptide (VIP) in the anaesthetized dog. Neuropeptides 2001;35:238-243.
7. Fishbein VA, Coy DH, Hocart SJ, Jiang NY, Mrozinski JE Jr, Mantey SA, Jensen RT: A chimeric VIP-PACAP analogue but not VIP pseudopeptides function as VIP receptor antagonists. Peptides 1994;15:95-100.
8. 17] VIP. Am J Physiol 1986;250:G553-G557.
9. Hirose M, Furukawa Y, Nagashima Y, Lakhe M, Chiba S: Pituitary adenylate cyclase-activating polypeptide-27 causes a biphasic chronotropic effect and atrial fibrillation in autonomically decentralized, anesthetized dogs. J Pharmacol Exp Ther 1997;283:478-487.
10. Hill MRS, Wallick DW, Mongeon L, Martin PJ, Levy MN: Vasoactive intestinal polypeptide antagonists attenuate vagally induced tachycardia in the heart. Am J Physiol 1995; 269:H1467-H1472.
11. 17] VIP in the awake dog. Peptides 1991;12:989-993.
12. Roossien A, Brunsting JR, Nijmeijer A, Zaagsma J, Zijlstra WG: Effects of vasoactive intestinal polypeptide on heart rate in relation to vagal cardioacceleration in conscious dogs. Cardiovasc Res 1997;33:392-399.
13. Markos F, Snow HM: Effects of vasoactive intestinal polypeptide (VIP) on vagal control of heart rate in the anaesthetized dog. Ir J Med Sci 1998;168:71.
14. Kappagoda CT, Linden RJ, Snow HM: An approach to the problems of acid-base balance. Clin Sci (Colch) 1970;39:169-182.
15. Henning RJ, Feliciano L, Coers CM: Vagal nerve stimulation increases right ventricular contraction and relaxation and heart rate. Cardiovasc Res 1996;32:846-853.
16. Feliciano L, Henning RJ: Vagal nerve stimulation releases vasoactive intestinal peptide which significantly increases coronary artery blood flow. Cardiovasc Res 1998;40:45-55.
17. Feliciano L, Henning RJ: Vagal nerve stimulation during muscarinic and beta-adrenergic blockade causes significant coronary artery dilation. J Auton Nerv Syst 1998;68:78-88.
18. Christophe J: Type I receptors for PACAP (a neuropeptide even more important than VIP?). Biochim Biophys Acta 1993;1154:183-199.
19. Laburthe M, Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P: Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein-linked receptors: Structure-function relationship with special reference to the human VIP-1 receptor. Ann NY Acad Sci 1996;805: 94-109.
20. O'Donnell M, Garippa RJ: O'Neill NC, Bolins DR, Cottrell JM: Structure-activity studies of vasoactive intestinal polypeptide. J Biol Chem 1991;266:6389-6392.
21. Rosselin G, Anteunis A, Astesano A, Boissard C, Gali P, Hejblum G, Marie JC: Regulation of the vasoactive intestinal peptide receptor. Ann NY Acad Sci 1988;527:220-237.
22. Svoboda M, De Neef P, Tastenoy M, Christophe J: Molecular characteristics and evidence for internalization of vasoactive-intestinal-peptide (VIP) receptors in the tumoral rat-pancreatic acinar cell line AR 4-2 J. Eur J Biochem 1988;176:707-713.
23. Luis J, Martin JM, el Battari A, Marvaldi J, Pichon J: The vasoactive intestinal peptide (VIP) receptor: Recent data and hypothesis. Biochimie 1988;70:1311-1322.